| Name | Title | Contact Details |
|---|---|---|
Marc Albers |
Vice President of Information Technology | Profile |
ANX Home Healthcare provides physician-ordered skilled nursing and health care services to homebound patients recovering from illness or injury. We have worked with physicians and families in developing custom home care solutions for patients requiring specialists in: • Wound care • Diabetes management • Cardiac rehabilitation • Physical therapy • Occupational therapy • Speech therapy • Nutritional assessments • Dietary counseling Our services are provided by a highly skilled interdisciplinary team of experts with over 75 years of combined experience in the health care industry. We pride ourselves in our ability to quickly respond to physician and clinician requests for patient home care. Best of all, you can count on us to provide service 24/7. With a team of full-time clinicians, we are able to initiate start of care within 24 hours. Established by Thomas Allandale Rocas III (RN, BSN, Certified Wound Care Specialist) and Lisa Mangubat (RN, BSN) in August 2007 with a vision of client-focused quality care and service for home-bound patients, ANX Home Healthcare is now in our ninth year of practice in the San Francisco Bay Area. We remain committed to providing competent and reliable care utilizing cutting-edge technology.
Capital Home Health Care is a Leesburg, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
San Luis Valley HMO is a Alamosa, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Health Benchmarks Inc is a Woodland Hills, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Alector is combining state-of-the-art antibody technology and recent discoveries in neuroimmunology and human genetics to develop novel therapeutics for Alzheimer`s disease, other forms of dementia, and mechanistically related neurodegenerative disorders. Alector`s strategy is to efficiently generate and validate antibody drugs with unique functional properties that engage key disease-altering targets. This approach is enabled by a strategic alliance with Adimab, the industry leader in discovery and optimization of antibody therapeutics. Alector is currently developing leads for 4 major targets and anticipates taking 2 of these through pre-clinical development and IND enabling studies within 24 months. Alector has incorporated a highly integrated and lean biotechnology structure with extensive outsourcing that supports core scientific and management teams.